Indication-specific pricing for cancer drugs

JAMA - Journal of the American Medical Association

Volumn 312, Issue 16, 2014, Pages 1629-1630

  Bach, Peter B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; ERLOTINIB; PACLITAXEL; TRASTUZUMAB;

BREAST CANCER; BREAST METASTASIS; CANCER SURVIVAL; CANCER THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INDICATION; DRUG RESEARCH; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEALTH CARE SYSTEM; HUMAN; INSURANCE; MALIGNANT NEOPLASTIC DISEASE; MEDICARE; METASTASIS; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PRACTICE GUIDELINE; PRESCRIPTION; QUALITY CONTROL; QUALITY OF LIFE; SHORT SURVEY; TREATMENT INDICATION; ARTICLE; COST CONTROL; ECONOMICS; EUROPE; HEALTH CARE POLICY; UNITED STATES;

ANTINEOPLASTIC AGENTS; COST CONTROL; DRUG COSTS; EUROPE; HEALTH POLICY; UNITED STATES;

EID: 84908150068     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.13235     Document Type: Short Survey

References (9)

1. IMS Institute for Healthcare Informatics. Medicine use and shifting costs of healthcare. http://www.imshealth.com/cds/imshealth/Global/Content/Corporate/IMS%20Health%20Institute/Reports/Secure/IIHI-US-Use-of-Meds-for-2013.pdf. Accessed July 23, 2014.
2. Bach PB. Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med. 2009;360(6):626-633.
3. Kupferschmidt K. Germany moves to lower drug prices. CMAJ. 2011;183(2):77-78.
4. ASCO in Action Brief: Value in Cancer Care. http://www.asco.org/advocacy/asco-action-brief-value-cancer-care. Accessed July 22, 2014.
5. Dranitsaris G, Cottrell W, Spirovski B, Hopkins S. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer. J Oncol Pharm Pract. 2009;15(2):67-78.
6. Gabriela Chiorean E, Whiting S, Binder G, et al. Cost-effectiveness of nab-paclitaxel plus gemcitabine versus erlotinib plus gemcitabine in metastatic pancreatic cancer. J Clin Oncol. 2014;32(3) (suppl):353.
7. National Institute for Health and Care Excellence (NICE). Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck: Costing Report. http://www.nice.org.uk/guidance/TA145. Accessed September 11, 2014.
8. Chen W, Jiang Z, Shao Z, Sun Q, Shen K. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer. Value Health. 2009;12(suppl 3):S82-S84.
9. Drugs@FDA: FDA Approved Drug Products. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed July 25, 2014.